Gynaecological Cancer – Medical News Asia

U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

8 December 2020/19 Comments/in Gastrointestinal Cancer, Genitourinary Cancer, Gynaecological Cancer, Haematology, Head and Neck Cancer, Lung Cancer, Oncology, Melanoma & Skin Cancer, Immunotherapy, AE Management, irAE Management/by Stijn van den Borne, MSc

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

First liquid biopsy for NSCLC to receive FDA approval

7 September 2020/0 Comments/in Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, US FDA Onc\Haem Approvals, Gynaecological Cancer, Lung Cancer, Oncology, Targeted Therapies/by Kirsty LEE

The development of new targeted therapies for non-small cell lung cancer (NSCLC) in recent years has changed the standard of care for the later stages of NSCLC in specific population groups.

ESMO releases the first guideline on NGS testing in cancers

7 September 2020/0 Comments/in Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynaecological Cancer, Lung Cancer, Oncology, Targeted Therapies, Pathology/by Kirsty LEE

Precision therapies were first approved for cancer in 1998, when trastuzumab was approved for HER2+ breast cancer, opening the door for other targeted therapies such as imatinib for Philadelphia chromosome-positive chronic myelogenous leukaemia.

Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society

13 August 2020/0 Comments/in Gynaecological Cancer, Infectious Disease, Head and Neck Cancer, Human Papillomavirus, Oncology, Vaccines/by Kirsty LEE

Human papillomavirus (HPV) is one of the most common causes of sexually transmitted disease worldwide. HPV is associated with a variety of clinical conditions that can range from cutaneous warts to cervical or anal cancer. Cervical cancer is the third most common cancer in women in the United States, and may constitute up to 25% of all female cancers in developing countries.

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

24 January 2020/0 Comments/in Gynaecological Cancer, Oncology, Chemotherapy, Targeted Therapies/by Christy HC CHEUNG, BSc

KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

24 April 2019/0 Comments/in Gynaecological Cancer, Haematology, Oncology, Chemotherapy, Immunotherapy/by Stijn van den Borne, MSc

Immunotherapy with programmed death 1 (PD-1) antibody pembrolizumab led to an objective response rate (ORR) of 14.6% in previously treated advanced cervical cancer patients with PD-L1–positive disease, as reported by Chung et al. on behalf of the KEYNOTE-158 investigators in the Journal of Clinical Oncology.

Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer

22 December 2018/0 Comments/in US FDA Onc\Haem Approvals, Gynaecological Cancer, Oncology, Targeted Therapies/by scienterrific

On 19 December 2018, the FDA approved olaparib (Lynparza®, AstraZeneca) as a maintenance treatment for adult advanced epithelial ovarian, fallopian tube or primary peritoneal cancer patients who achieving a complete or partial response to first-line platinum-based chemotherapy and who have deleterious germline or somatic BRCA-mutatations (gBRCAm or sBRCAm) by an FDA-aproved test or who are suspected to have deleterious BRCA-mutatations (BRCAm).

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

7 October 2018/0 Comments/in Gynaecological Cancer, Oncology, Chemotherapy, Immunotherapy/by scienterrific

Adding ipilimumab (IPI [Yervoy®, Bristol-Myers Squibb]) to nivolumab (NIVO [Opdivo®, Bristol-Myers Squibb]) induction followed by maintenance with single-agent NIVO had a superior objective tumour response rate and progression-free survival (PFS) when compared to NIVO alone in patients with persistent or recurrent epithelial ovarian cancer.

Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers

14 June 2018/0 Comments/in US FDA Onc\Haem Approvals, Gynaecological Cancer, Oncology, Chemotherapy, Targeted Therapies/by scienterrific

On June 13, 2018, the FDA approved bevacizumab (AvastinⓇ, Genentech, Inc.) in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab for use after surgical resection in patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1

13 June 2018/0 Comments/in US FDA Onc\Haem Approvals, Gynaecological Cancer, Oncology, Immunotherapy, Translational Research/by scienterrific

On June 12, 2018 the FDA approved pembrolizumab (KeytrudaⓇ, Merck & Co. Inc.) for patients with chemotherapy-refractory recurrent or metastatic (r/m) cervical cancer and with a combined positive score (CPS)≥1 PD-L1 level expression.